Evolus Inc reports results for the quarter ended in March - Earnings Summary

Evolus

08/05/2024 08:28

* Evolus Inc  EOLS.OQ  reported a quarterly adjusted loss
of 9
cents​​ per share for the quarter ended in March, higher than
the same quarter last year, when the company reported EPS of -15
cents.  The mean expectation of six analysts for the quarter was
for a loss of 10 cents per share. Wall Street expected
results to range from -20 cents to -5 cents per share.
    * Revenue rose 42.2% to $59.33 million from a year ago;
analysts
expected $57.32 million. 
    * Evolus Inc's reported EPS for the quarter was a loss of 22
cents​.
    * The company reported a quarterly loss of $13.11 million.
    * Evolus Inc shares had fallen by 4.1% this quarter and
gained 27.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 24.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Evolus Inc is
$23.00 
This summary was machine generated from LSEG data May 8 at 07:28
a.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.10          -0.09          Beat
 Dec. 31 2023      -0.07          -0.12          Missed
 Sep. 30 2023      -0.17          -0.16          Beat
 Jun. 30 2023      -0.19          -0.19          Met